Antibodies to SOX2 were detected by ELISA in 37/61 (61%) patients with LEMS-SCLC, and 4/65 (6%) patients with non-tumour LEMS (P < .0001) (Table 1). This evidence concerns the gene SOX2 and neoplasm.